会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明公开
    • 올리고뉴클레오타이드 및 비독성 다당체를 포함하는면역보조제
    • 包括寡核苷酸和非毒性LPS的ADJUVANT
    • KR1020060117387A
    • 2006-11-17
    • KR1020050038771
    • 2005-05-10
    • 아이진 주식회사이나경
    • 이나경안보영유원일조양제
    • A61K31/7088
    • A61K39/39A61K31/7088A61K2039/55561A61K2039/55572
    • An immunoadjuvant comprising oligonucleotide and non-toxic lipopolysaccharide(LPS) is provided to improve safety, efficiency and specificity in induction of immune responses compared to using single of oligodeoxynucleotide immunoadjuvant by using bacteria-derived LPS. The immunoadjuvant composition comprises (a) oligodeoxynucleotide(ODN) and (b) non-toxic lipopolysaccharide(LPS) isolated from bacteria, wherein the oligodeoxynucleotide has more than 20 mer and optionally contains CG motif; the cytosine base of the oligodeoxynucleotide is optionally methylated; the oligodeoxynucleotide comprises the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; the non-toxic polymer derived from lipopolysaccharide(LPS) has molecular weight of 2000 to 10000 dalton; the bacterium is Escherichia coli or Mycobacterium; and the immunoadjuvant composition is used as adjuvant of HBV(hepatitis B virus) vaccine.
    • 提供包含寡核苷酸和无毒性脂多糖(LPS)的免疫佐剂以提高与使用细菌来源的LPS使用单个寡脱氧核苷酸免疫佐剂相比,在诱导免疫应答方面的安全性,效率和特异性。 免疫佐剂组合物包含(a)寡脱氧核苷酸(ODN)和(b)从细菌中分离的无毒性脂多糖(LPS),其中所述寡脱氧核苷酸具有多于20个聚体并且任选地包含CG基序; 寡脱氧核苷酸的胞嘧啶碱基任选被甲基化; 寡脱氧核苷酸包含SEQ ID NO:1,SEQ ID NO:2或SEQ ID NO:3的核苷酸序列; 衍生自脂多糖(LPS)的无毒性聚合物的分子量为2000〜10000道尔顿; 该细菌是大肠杆菌或分枝杆菌; 免疫佐剂组合物用作HBV(乙型肝炎病毒)疫苗的佐剂。
    • 4. 发明公开
    • 안지오포이에틴 분비 유발 폴리펩타이드
    • 多糖诱导安非他酮的分泌
    • KR1020070011371A
    • 2007-01-24
    • KR1020067021091
    • 2004-03-31
    • 아이진 주식회사
    • 조양제안보영김두식유원일
    • C07K14/515A61K38/00
    • A polypeptide is provided to be able to induce the secretion of angiopoietin, thereby being used as a therapeutic agent to facilitate a formation of a normal structure of blood vessel. The protein for inducing an angiopoietin-1 secretion comprises an amino acid sequence described in SEQ ID NO 1. The therapeutic agent for treating angiogenesis-related diseases such as pulmonary hypertension, ischemic myocardium, skin flap survival, heart failure, acute hindlimb ischemia and ocular diseases comprises an effective amount of the angiopoietin-1 secretion-inducing proteins comprising the protein of SEQ ID NO 1.
    • 提供多肽以能够诱导血管生成素的分泌,由此用作治疗剂以促进血管的正常结构的形成。 用于诱导血管生成素-1分泌的蛋白质包含SEQ ID NO 1中所述的氨基酸序列。用于治疗血管生成相关疾病如肺动脉高压,缺血心肌,皮瓣存活,心力衰竭,急性后肢缺血和眼睛的治疗剂 疾病包括有效量的包含SEQ ID NO 1的蛋白质的血管生成素-1分泌诱导蛋白。
    • 7. 发明公开
    • 특정염기 다양성에 의한 당뇨망막증 진단방법, 그 DNA 절편및 그 프라이머
    • 通过单核多核苷酸诊断糖尿病肾病的方法,其DNA片段及其前体
    • KR1020080026099A
    • 2008-03-24
    • KR1020077028801
    • 2005-05-18
    • 아이진 주식회사
    • 조양제안보영권오웅김석준홍선표유왕돈김수옥
    • C12N15/10C12N15/11C12Q1/68
    • C12Q1/6883
    • A DNA fragment and a primer for diagnosing diabetic retinopathy are provided to be used for predicting possibility to metastasize into retinal complications, thereby being used for preventing and treating diseases. A DNA fragment for diagnosing diabetic retinopathy is selected from the group consisting of: (a) a DNA fragment having a 2029th T base of a vascular endothelial growth factor(VEGF) gene; (b) a DNA fragment having a 1514th T base of a VEGF gene; and (c) a DNA fragment having a 4612th G base of a VEGF receptor gene. A forward primer for diagnosing diabetic retinopathy is selected from the group consisting of: a primer of SEQ ID : NO. 2 binding to the DNA fragment of (a); a primer of SEQ ID : NO. 7 binding to the DNA fragment of (b); and a primer of SEQ ID : NO. 12 binding to the DNA fragment of (c). A reverse primer for diagnosing diabetic retinopathy is selected from the group consisting of: a primer of SEQ ID : NO. 3 binding to the DNA fragment of (a); a primer of SEQ ID : NO. 8 binding to the DNA fragment of (b); and a primer of SEQ ID : NO. 13 binding to the DNA fragment of (c). A method for diagnosing diabetic retinopathy uses DNA sequencing, PCR-SSCP(Polymerase chain reaction-Single stranded conformation polymorphism), allele-Specific hybridization, an oligo-ligation method, mini-sequencing, enzymatic cleavage or DNA chip by using the DNA fragment as a template.
    • 提供用于诊断糖尿病性视网膜病变的DNA片段和引物,用于预测转移到视网膜并发症中的可能性,从而用于预防和治疗疾病。 用于诊断糖尿病性视网膜病变的DNA片段选自:(a)具有血管内皮生长因子(VEGF)基因的第2029位T碱基的DNA片段; (b)具有VEGF基因的第1514位T碱基的DNA片段; 和(c)具有VEGF受体基因的第4612位G碱基的DNA片段。 用于诊断糖尿病性视网膜病变的正向引物选自:SEQ ID NO: 2结合(a)的DNA片段; SEQ ID NO:1的引物。 7结合(b)的DNA片段; 和SEQ ID NO:1的引物。 12结合(c)的DNA片段。 用于诊断糖尿病性视网膜病变的反向引物选自:SEQ ID NO: 3结合(a)的DNA片段; SEQ ID NO:1的引物。 8结合(b)的DNA片段; 和SEQ ID NO:1的引物。 13结合(c)的DNA片段。 诊断糖尿病性视网膜病变的方法使用DNA片段作为DNA测序,PCR-SSCP(聚合酶链反应 - 单链构象多态性),等位基因特异性杂交,寡连接法,微型测序,酶切或DNA切片 一个模板